ID   NALM-19
AC   CVCL_1835
SY   NALM19; Nalm19
DR   CLO; CLO_0037187
DR   ArrayExpress; E-MTAB-2770
DR   BioSample; SAMN03473520
DR   BioSample; SAMN10988461
DR   cancercelllines; CVCL_1835
DR   Cell_Model_Passport; SIDM01685
DR   Cosmic; 999733
DR   DepMap; ACH-000130
DR   DSMZ; ACC-522
DR   DSMZCellDive; ACC-522
DR   GEO; GSM887345
DR   GEO; GSM888421
DR   IARC_TP53; 30126
DR   JCRB; JCRB1822
DR   LiGeA; CCLE_296
DR   LINCS_LDP; LCL-1093
DR   PharmacoDB; NALM19_979_2019
DR   Progenetix; CVCL_1835
DR   Wikidata; Q54907400
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=1664237;
RX   PubMed=9680106;
RX   PubMed=22460905;
RX   PubMed=26589293;
RX   PubMed=30285677;
RX   PubMed=30629668;
RX   PubMed=30894373;
RX   PubMed=31068700;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Population: Japanese.
CC   Doubling time: 29 hours (PubMed=1664237); ~50-70 hours (DSMZ=ACC-522).
CC   HLA typing: A*11:01,33:03; B*40:06,54:01; C*01:02,15:02 (PubMed=26589293).
CC   Omics: Deep exome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=1.76%; Native American=0.1%; East Asian, North=79.97%; East Asian, South=14.34%; South Asian=0.01%; European, North=0%; European, South=3.83% (PubMed=30894373).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
ST   Source(s): DSMZ
ST   Amelogenin: X,Y
ST   CSF1PO: 9,10
ST   D13S317: 8,12
ST   D16S539: 11,13
ST   D18S51: 15,17.3
ST   D19S433: 13
ST   D21S11: 30,31
ST   D2S1338: 19,25
ST   D3S1358: 16,18
ST   D5S818: 10,11
ST   D7S820: 10,11
ST   D8S1179: 13,14
ST   FGA: 21,23
ST   Penta D: 10
ST   Penta E: 15,17
ST   TH01: 9
ST   TPOX: 8,11
ST   vWA: 17,20
DI   NCIt; C8644; B acute lymphoblastic leukemia
DI   ORDO; Orphanet_99860; Precursor B-cell acute lymphoblastic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_L055 ! B239
OI   CVCL_L056 ! B240
SX   Male
AG   26Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 30
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=1664237;
RA   Matsuo Y., Ariyasu T., Adachi T., Tsubota T., Imanishi J.,
RA   Minowada J.;
RT   "Establishment and characterization of a bi-phenotypic leukemic cell
RT   line, NALM-19, from a patient with acute leukemia.";
RL   Hum. Cell 4:257-260(1991).
//
RX   PubMed=9680106; DOI=10.1016/S0145-2126(98)00050-2;
RA   Matsuo Y., Drexler H.G.;
RT   "Establishment and characterization of human B cell precursor-leukemia
RT   cell lines.";
RL   Leuk. Res. 22:567-579(1998).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=30285677; DOI=10.1186/s12885-018-4840-5;
RA   Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X.,
RA   Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H.,
RA   Koeffler H.P.;
RT   "Profiling the B/T cell receptor repertoire of lymphocyte derived cell
RT   lines.";
RL   BMC Cancer 18:940.1-940.13(2018).
//
RX   PubMed=30629668; DOI=10.1371/journal.pone.0210404;
RA   Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.;
RT   "Screening human cell lines for viral infections applying RNA-Seq data
RT   analysis.";
RL   PLoS ONE 14:E0210404-E0210404(2019).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//